Moreover, treatment with pemafibrate decreased the mRNA expression of fibrosis-related genes, such as Tgfb, Col1a1, and Acta2. This result is consistent with the findings of previous studies suggesting that PPARα agonists can ameliorate hepatic fibrosis by acting directly on hepatic PPARα [35, 42]. Here, ACTA2 is linked to Hepatic fibrosis.